Swiss drug major Novartis has agreed to acquire the animal health business of Sankyo Lifetech Co, expanding the group's presence in this sector in Japan.
Under the agreement, the financial terms of which were not disclosed, Sankyo Lifetech, a subsidiary of Sankyo Co, will transfer its animal health business to a new company that Novartis Animal Health KK has agreed to acquire. The transaction is expected to close at the end of March 2007. This includes the transfer of consenting staff and all marketing authorizations and intellectual property related to the commercialized brands and R&D portfolio of Sankyo Lifetech's animal health business, which generated $48.0 million in product sales in the fiscal year ending in March 2006.
Novartis and Sankyo started this collaboration in the early 1990s, which was particularly successful in the development and commercialization of milbemycin oxime. This broad-spectrum parasiticide is marketed by Sankyo under the trade names Milbemycin A (heartworm control) and Systec (combination product to control heartworm and fleas), which correspond to the Novartis brands Interceptor and Sentinel.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze